205535-74-6
205535-74-6
Chemical Structure
KR30031
- CAS No.: 205535-74-6
- Formula:C26H34N2O4
- Molecular Weight:438.56
IUPAC Name: 1-(3-((3,4-dimethoxyphenethyl)(methyl)amino)propyl)-4,5-dimethoxy-2,3-dihydro-1H-indene-1-carbonitrile
InChIKey: VLSLFQMGJUJBQJ-UHFFFAOYSA-N
SMILES: N#CC1(CCC2=C1C=CC(OC)=C2OC)CCCN(C)CCC3=CC=C(C(OC)=C3)OC
Biological Activity: KR30031, a Verapamil (HY-14275) analog, is an orally active P-glycoprotein (P-gp) inhibitor. KR30031 enhances the cytotoxicity of anticancer agents by inhibiting P-gp with fewer cardiovascular adverse effects. KR30031 can be used to study multidrug resistance (MDR) reversal in cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
KR30031 | KR30031, a Verapamil (HY-14275) analog, is an orally active P-glycoprotein (P-gp) inhibitor. KR30031 enhances the cytotoxicity of anticancer agents by inhibiting P-gp with fewer cardiovascular adverse effects. KR30031 can be used to study multidrug resistance (MDR) reversal in cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lee BH, et al. Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity. Anticancer Drugs. 2003 Feb;14(2):175-81. [Content Brief]
- [2]. Woo JS, et al. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res. 2003 Jan;20(1):24-30. [Content Brief]
